Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer

Chenliang Wang, Ming Zhu, Lei Bao, Vanina Toffessi Tcheuyap, James Brugarolas, Weibo Luo, Yingfei Wang · 2026

Read Alkylating agents activate an SLFN11-dependent vulnerability that confers PARP-1 inhibitor sensitivity in kidney cancer by Chenliang Wang, Ming Zhu, Lei Bao, Vanina Toffessi Tcheuyap, James Brugarolas, Weibo Luo, Yingfei Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471403.txt.

Description

Wang and co-authors searched for a way to make kidney tumors that resist PARP inhibitors, a class of DNA-repair-blocking drugs, vulnerable to them. Their 2026 laboratory study screened DNA-damaging alkylating agents for synergy with PARP blockade in clear cell renal cell carcinoma, the subtype behind about 80% of kidney cancers. Tumors with normal BRCA genes, usually unmoved by these inhibitors, were the specific target.

Two agents, temozolomide and streptozocin, pushed the PARP-1 enzyme into overdrive and created the opening the inhibitors exploit. The effect depended on SLFN11, a protein missing in about 45% of cancer cells, which marked which tumors responded. Combinations shrank tumors in mouse xenografts and in patient-derived tumor grafts, and every drug involved is already approved for cancer treatment.

Catalog record

CREATORChenliang Wang, Ming Zhu, Lei Bao, Vanina Toffessi Tcheuyap, James Brugarolas, Weibo Luo, Yingfei Wang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13471403

Browse the full library · About the Tower of Babel